---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-037588"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:06.708298+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025

## Summary
- Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.
- Cash $851M as of Dec 31, 2024; runway into mid-2027.
- KT-621 Phase 1 SAD/MAD data June 2025; Phase 1b AD starts 2Q25 with data 4Q25; Phase 2b AD/asthma 4Q25/1Q26.
- KT-295 (TYK2) Phase 1 starts 2Q25 with data 4Q25; new first-in-class program announced May 2025.
- Director Leigh Morgan not standing for reelection; no disagreement with company.

## SEC filing metadata
- accession: 0001193125-25-037588
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/0001193125-25-037588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-037588
- JSON: https://secwatch.observer/filing/0001193125-25-037588.json
- Plain text: https://secwatch.observer/filing/0001193125-25-037588.txt

## Key facts
- Executive change
  Leigh Morgan departed as Director at Kymera Therapeutics, Inc..
  - Action: does not intend to stand for reelection
  - Role: Director
  source text: On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/0001193125-25-037588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.